Alfasigma buys Nordic Pharma, adding rheumatology reach across Europe, Canada and Japan
What's the deal? AlfasigmaDealroom has a profile for this one. Try Dealroom → has signed a share purchase agreement with SEVER Life SciencesDealroom has a profile for this one. Try Dealroom → to acquire 100% of Nordic GroupDealroom has a profile for this one. Try Dealroom → B.V. (Nordic PharmaDealroom has a profile for this one. Try Dealroom →), a privately owned specialty pharmaceutical company with direct operations in Europe, Canada and Japan. The Italian drugmaker gains Nordic Pharma's rheumatoid arthritis business, led by the Nordimet methotrexate franchise, plus portfolios in women's health, critical care and ophthalmology. Terms were not disclosed.
What's the endgame? Alfasigma is building a global specialty and rare disease business focused on gastroenterology and immunology. The deal adds direct operations in 18 countries across Europe and commercial platforms in Canada and Japan, plus 265 employees. It also expands Alfasigma's rheumatology portfolio, which already includes the Jyseleca franchise.
Why now? The acquisition supports what the company calls its M&A-led growth strategy. It follows recent portfolio moves, including the purchase of Jyseleca in inflammatory diseases and a licensing agreement with GSK for linerixibat.
"The acquisition of Nordic Pharma marks a decisive step forward in that journey, strengthening our European presence and expanding our rheumatology portfolio," said Francesco Balestrieri, chief executive officer of Alfasigma.
What could go wrong? The transaction is subject to customary closing conditions, including any required regulatory clearances. Until those are met, the deal is not final.
The signal: Alfasigma, which employs roughly 4,000 people and sells in more than 100 markets, is using acquisitions and licensing to move from primary care into higher-value specialty and rare disease treatments. Bolt-on deals like this let mid-sized drugmakers expand therapeutic depth and geographic reach without building from scratch. For SEVER, the sale sharpens its focus on its remaining development and manufacturing businesses.
Read more: Associated Press
Image credit: foteih
